Journal Club

Papers worth reading, each with the study's conclusion and a link to the source. Updated as new studies land.

Journal Clubupdated as studies land

Showing 1 of 1 paper

Bladder CancerThe LancetAdded 2026-05-30

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Conclusion: Adding 1 year of durvalumab to BCG induction and maintenance significantly improved disease-free survival versus BCG alone in BCG-naive, high-risk NMIBC (HR 0.68), with a manageable safety profile.

Read on PubMed

No papers yet — check back soon.